{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T09:02:06Z","timestamp":1772269326644,"version":"3.50.1"},"reference-count":32,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T00:00:00Z","timestamp":1047340800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J of Cellular Biochemistry"],"published-print":{"date-parts":[[2003,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>AIDS\u2010related Kaposi's sarcoma (KS) is the most common HIV\u2010related malignancy. In some respects, KS is analogous to other angioproliferative diseases, in that KS lesions are highly vascularized and promoted by inflammatory cytokines. However, unlike other cancers or inflammatory mediated vascular diseases, KS is unique in that the KS lesional cells both express and respond to the complete angiogenic cytokines vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF). Therefore, the angiogenic phenotype, which is crucial for cancer progression, is inherent to KS tumor cells. Due to the recognized importance of angiogenesis in cancer progression, numerous angiostatic agents are being investigated as potential therapeutic agents. One such agent is endostatin, which is a 20\u2010kDa carboxyl\u2010terminal fragment of collagen XVIII that has demonstrated potent angiostatic activities at both the in vivo and in vitro levels. Since endostatin is recognized as a potent angiostatic agent, the majority of in vitro endostatin studies have evaluated its effects on endothelial cells. Although KS cells are speculated to arise from endothelial cell precursors and KS lesions are highly vascularized, no previous studies have investigated endostatin\u2013KS cell interactions. This present study evaluated endostatin's effects on KS tumor cell: (i) signal transduction (endostatin internalization and transcription factor activation), and (ii) migration and invasion (functional activity assays and tropomysin co\u2010localization). Our results show that KS cells rapidly internalize endostatin and that endostatin initiates activation of the transcription activating factors nuclear factor\u2010\u03baB (NF\u2010\u03baB) and activating protein 1 (AP\u20101). Our data also show that internalized endostatin co\u2010localizes to tropomysin microfilaments and acts to inhibit KS cell migration and invasion in response to the clinically relevant angiogenic cytokines VEGF and bFGF. As a consequence of its combined angiostatic and antitumorigenic activities, endostatin could provide dual therapeutic benefits for patients with mucocutaneous KS. J. Cell. Biochem. 89: 133\u2013143, 2003. Published 2003 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/jcb.10489","type":"journal-article","created":{"date-parts":[[2003,4,3]],"date-time":"2003-04-03T17:02:57Z","timestamp":1049389377000},"page":"133-143","source":"Crossref","is-referenced-by-count":11,"title":["AIDS\u2010related Kaposi's sarcoma cells rapidly internalize endostatin, which co\u2010localizes to tropomysin microfilaments and inhibits cytokine\u2010mediated migration and invasion"],"prefix":"10.1002","volume":"89","author":[{"given":"Susan R.","family":"Mallery","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A.","family":"Morse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralph F.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Pei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory M.","family":"Ness","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer E.","family":"Bradburn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"Renner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David E.","family":"Schuller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fredika M.","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2003,4,2]]},"reference":[{"key":"e_1_2_5_2_1","first-page":"473","article-title":"Correlation between AIDS\u2010related Kaposi sarcoma histologic grade and in vitro behavior: Reduced exogenous growth factor requirements for isolates from high grade lesions","volume":"28","author":"Bailer RT","year":"1995","journal-title":"Lymphology"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.17.11721"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.11.3403"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199512283332608"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(19)49853-0"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199958010-00003"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001622-199509000-00011"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0891-5849(00)00218-5"},{"key":"e_1_2_5_10_1","first-page":"7669","article-title":"Continuous administration of endostatin by intraperitoneally implanted osmotic pump improve the efficacy and potency of therapy in a mouse xenograft tumor model","volume":"61","author":"Kisker O","year":"2001","journal-title":"Cancer Res"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-5793(02)02742-4"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0074-7696(08)61619-8"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M100743200"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-4644(19990501)73:2<259::AID-JCB12>3.0.CO;2-3"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/21.9.1647"},{"key":"e_1_2_5_16_1","first-page":"2817","article-title":"Controlled release of doxorubicin from poly(lactide\u2010co\u2010glycolide) microspheres significantly enhances cytotoxicity against cultured AIDS\u2010related Kaposi's sarcoma cells","volume":"20","author":"Mallery SR","year":"2000","journal-title":"Anticancer Res"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.3.979"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001622-199809000-00008"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/00001622-199409000-00009"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.87.11.4068"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0955-0674(99)00022-8"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81848-6"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1006\/scbi.2000.0337"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.98.3.1024"},{"key":"e_1_2_5_25_1","first-page":"493","article-title":"The expression of endothelial cell surface antigens by AIDS\u2010associated Kaposi's sarcoma: Evidence for a vascular endothelial cell origin","volume":"122","author":"Rutger JL","year":"1986","journal-title":"Am J Pathol"},{"key":"e_1_2_5_26_1","first-page":"1433","article-title":"Vascular endothelial growth factor and basic fibroblast growth factor present in Kaposi's sarcoma are induced by inflammatory cytokines and synergize to promote vascular permeability and KS lesion development","volume":"152","author":"Samaniego F","year":"1998","journal-title":"Am J Pathol"},{"key":"e_1_2_5_27_1","first-page":"633","volume-title":"Cancer chemotherapy and biological response modifiers","author":"Shah MH","year":"2002"},{"key":"e_1_2_5_28_1","doi-asserted-by":"publisher","DOI":"10.1096\/fsb2fj991083com"},{"key":"e_1_2_5_29_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.9.3619"},{"key":"e_1_2_5_30_1","doi-asserted-by":"publisher","DOI":"10.1006\/scbi.2000.0379"},{"key":"e_1_2_5_31_1","doi-asserted-by":"publisher","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v12.i1.10"},{"key":"e_1_2_5_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-2952(00)00444-5"},{"key":"e_1_2_5_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/71916"}],"container-title":["Journal of Cellular Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjcb.10489","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jcb.10489","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T12:55:28Z","timestamp":1696683328000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jcb.10489"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,4,2]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2003,5]]}},"alternative-id":["10.1002\/jcb.10489"],"URL":"https:\/\/doi.org\/10.1002\/jcb.10489","archive":["Portico"],"relation":{},"ISSN":["0730-2312","1097-4644"],"issn-type":[{"value":"0730-2312","type":"print"},{"value":"1097-4644","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,4,2]]}}}